Laborie Advances Ureteric Stricture Treatments with New Study
Landmark procedures launch the ENDURE 1 clinical study evaluating Optilume's safety and feasibility as a new minimally invasive option for patients with ureteric strictures.
Laborie Medical Technologies, a renowned name in the field of diagnostic and therapeutic devices, has recently announced notable progress in their clinical trials. The company has successfully carried out the initial procedures utilizing the Optilume Ureteric Drug-Coated Balloon (DCB), marking a pivotal moment for treatment options available to patients encountering benign ureteric strictures.
The pioneering procedures were performed by Dr. Jaime Landman at University of California Irvine Health, alongside a dedicated team of investigators participating in the ENDURE 1 study. This multi-center trial, designed to examine the safety and feasibility of the Optilume DCB, focuses on treating ureteric strictures as long as 4 centimeters. By combining mechanical dilation with the localized application of paclitaxel, a well-known antiproliferative medication, the Optilume system aims to reduce the recurrence of scar tissue while promoting long-lasting ureteral patency.
Ureteric strictures occur due to the narrowing of the ureters, often resulting from scar tissue formed following conditions such as kidney stones, surgical procedures, radiotherapy, or physical trauma. The consequences of ureteric strictures can be severe, leading to persistent pain, infections, and even kidney damage. Traditional treatments like repeat dilations or stenting often do not provide lasting relief, and in severe occurrences, reconstructive surgery may be required. The innovative Optilume DCB offers a minimally invasive alternative that may enhance recovery outcomes and diminish the frequency of repeat interventions.
"We are thrilled to reach this significant milestone for Optilume in treating ureters," commented Chris Smith, CEO of Laborie. "This enhancement builds upon the established clinical successes of Optilume in anterior urethral strictures and represents a considerable progression in our efforts to offer diverse treatment options for patients who have limited alternatives."
The ENDURE 1 study aims to recruit up to 60 patients from several sites across the U.S., with participants monitored for five years post-procedure. Essential objectives of the study include evaluating technical success rates, freedom from further treatments, improvements in kidney function, and patient-reported outcomes to gauge overall satisfaction with the treatment.
Dr. Landman emphasized the challenges faced by patients with ureteric strictures, expressing, "Patients dealing with ureteric strictures encounter very few long-lasting solutions, alongside significant hurdles including the potential for critical kidney damage. The groundbreaking combination of dilation and drug delivery offered by Optilume has the capability to revolutionize our approach to treating this historically difficult condition."
The Optilume Ureteric Drug-Coated Balloon is still being evaluated, and its use is restricted by federal regulations exclusively for investigational purposes, hence it is not yet available for commercial use.
About Laborie Medical Technologies
Laborie is a prominent global medical technology firm specializing in disciplines such as Urology, Urogynecology, Gastroenterology, Obstetrics, Gynecology, and Neonatal Health. With headquarters in Portsmouth, New Hampshire, the company is dedicated to manufacturing high-quality, impactful diagnostic and therapeutic tools that aim to uphold and restore patient dignity. Medical practitioners and healthcare facilities recognize Laborie as industry leaders, supported by a comprehensive clinical education and information initiative. Laborie is proud to be a part of Patricia Industries' portfolio.
Frequently Asked Questions
What is the ENDURE 1 study?
The ENDURE 1 study is a clinical trial evaluating the safety and feasibility of the Optilume Ureteric Drug-Coated Balloon in treating benign ureteric strictures.
Who is conducting the initial procedures for the study?
The initial procedures are being conducted by Dr. Jaime Landman at the University of California Irvine Health.
What are the primary goals of the ENDURE 1 study?
The study aims to assess technical success, freedom from retreatment, improvements in kidney function, and patient-reported outcomes.
How does the Optilume DCB work?
The Optilume DCB combines mechanical dilation with localized paclitaxel delivery to prevent scar tissue recurrence and improve ureteral patency.
What restrictions apply to the Optilume Ureteric Drug-Coated Balloon?
The device is for investigational use only and is not available commercially as it is limited by federal regulations.
